首页> 美国卫生研究院文献>The Journal of Clinical Investigation >Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?
【2h】

Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?

机译:RNAi的治疗应用:靶向mRNA的时间终于准备好了吗?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

With unprecedented speed, RNA interference (RNAi) has advanced from its basic discovery in lower organisms to becoming a powerful genetic tool and perhaps our single most promising biotherapeutic for a wide array of diseases. Numerous studies document RNAi efficacy in laboratory animals, and the first clinical trials are underway and thus far suggest that RNAi is safe to use in humans. Yet substantial hurdles have also surfaced and must be surmounted before therapeutic RNAi applications can become a standard therapy. Here we review the most critical roadblocks and concerns for clinical RNAi transition, delivery, and safety. We highlight emerging solutions and concurrently discuss novel therapeutic RNAi-based concepts. The current rapid advances create realistic optimism that the establishment of RNAi as a new and potent clinical modality in humans is near.
机译:RNA干扰(RNAi)以前所未有的速度发展,从其在低等生物中的基本发现发展成为一种强大的遗传工具,也许是我们针对多种疾病的最有前途的生物疗法。大量研究记录了RNAi在实验动物中的功效,并且正在进行第一批临床试验,因此迄今为止表明RNAi在人类中是安全使用的。然而,在治疗性RNAi应用成为标准疗法之前,还存在很多障碍,必须克服。在这里,我们回顾了临床RNAi过渡,递送和安全性的最关键障碍和关注。我们重点介绍新兴的解决方案,并同时讨论基于RNAi的新型治疗概念。当前的快速发展使人们对将RNAi建立为人类新的有效临床手段的现实乐观。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号